Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · IEX Real-Time Price · USD
-0.10 (-1.18%)
At close: Jul 17, 2024, 4:00 PM
+0.14 (1.67%)
After-hours: Jul 17, 2024, 7:09 PM EDT

Company Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.

Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) logo
Country Canada
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 57
CEO Robert Barrow

Contact Details

One World Trade Center, Suite 8500
New York, New York 10007
United States
Phone 212-220-6633
Website mindmed.co

Stock Details

Ticker Symbol MNMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001813814
CUSIP Number 60255C109
ISIN Number CA60255C8850
SIC Code 2833

Key Executives

Name Position
Robert Barrow Chief Executive Officer and Director
Schond L. Greenway M.B.A. Chief Financial Officer
Dr. Daniel Rollings Karlin M.A., M.D. Chief Medical Officer
Dr. Miriam Halperin Wernli Ph.D. Executive President
Dr. Scott M. Freeman M.D. Co-Founder and Clinical Advisor
Leonard Latchman Co-founder
Carrie F. Liao CPA, CGMA Vice President and Chief Accounting Officer
Mark R. Sullivan J.D. Chief Legal Officer and Corporate Secretary
Dr. Francois P. Lilienthal M.B.A., M.D. Chief Commercial Officer

Latest SEC Filings

Date Type Title
Jun 28, 2024 8-K Current Report
Jun 28, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Jun 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 25, 2024 144 Filing
Jun 25, 2024 144 Filing
Jun 25, 2024 144 Filing
Jun 20, 2024 8-K Current Report
Jun 11, 2024 8-K Current Report
May 8, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report